申请人:Curis, Inc.
公开号:US20140155606A1
公开(公告)日:2014-06-05
The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (I) below.
These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
本发明涉及以下公式(I)中含有金属离子结合基团的喹嗪衍生物。这些化合物具有增强和意外的抑制表皮生长因子受体酪氨酸激酶(EGFR-TK)的性质,并且在治疗EGFR-TK相关疾病和疾病,如癌症方面有用。这些化合物还可以作为HDAC抑制剂。